Michael Andrew Chambers net worth and biography

Michael Chambers Biography and Net Worth

Mr. Chambers co-founded Aldevron, based in Fargo, N.D., in 1998, and served as its chief executive officer for more than 20 years before serving as Executive Chairman of the Board until 2021 when Aldevron was acquired by Danaher Corporation. As founder, Mr. Chambers oversaw the growth of Aldevron into a world-class service organization, specializing in nucleic acid and protein production, antibody development, and custom services with operations in the United States and Europe. He currently serves on the Board of Directors at Calviri, Inc.

In 2018, Mr. Chambers was named one of the “100 Most Intriguing Entrepreneurs” by Goldman Sachs. He earned his bachelor’s degree in biotechnology, microbiology, and chemistry from North Dakota State University.

What is Michael Andrew Chambers' net worth?: The estimated net worth of Michael Andrew Chambers is at least $28.56 million as of August 14th, 2023. Mr. Chambers owns 246,996 shares of Sarepta Therapeutics stock worth more than $28,557,678 as of April 20th. This net worth evaluation does not reflect any other investments that Mr. Chambers may own. Learn More about Michael Andrew Chambers' net worth.
How do I contact Michael Andrew Chambers?: The corporate mailing address for Mr. Chambers and other Sarepta Therapeutics executives is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. Sarepta Therapeutics can also be reached via phone at (617) 274-4000 and via email at [email protected]. Learn More on Michael Andrew Chambers' contact information.
Has Michael Andrew Chambers been buying or selling shares of Sarepta Therapeutics?: Michael Andrew Chambers has not been actively trading shares of Sarepta Therapeutics within the last three months. Most recently, on Monday, August 14th, Michael Andrew Chambers bought 9,979 shares of Sarepta Therapeutics stock. The stock was acquired at an average cost of $109.47 per share, with a total value of $1,092,401.13. Following the completion of the transaction, the director now directly owns 246,996 shares of the company's stock, valued at $27,038,652.12. Learn More on Michael Andrew Chambers' trading history.
Who are Sarepta Therapeutics' active insiders?: Sarepta Therapeutics' insider roster includes Richard Barry (Director), M. Behrens (Director), Joseph Bratica (Insider), Michael Chambers (Director), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?: In the last twelve months, Sarepta Therapeutics insiders bought shares 4 times. They purchased a total of 120,071 shares worth more than $10,735,889.18. In the last twelve months, insiders at the biotechnology company sold shares 6 times. They sold a total of 37,096 shares worth more than $4,340,219.33. The most recent insider tranaction occured on March, 11th when Director Kathryn Jean Boor sold 761 shares worth more than $93,549.73. Insiders at Sarepta Therapeutics own 7.4% of the company. Learn More about insider trades at Sarepta Therapeutics.
Information on this page was last updated on 3/11/2024.

Michael Andrew Chambers Insider Trading History at Sarepta Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/14/2023	Buy	9,979	$109.47	$1,092,401.13	246,996
8/10/2023	Buy	34,867	$106.15	$3,701,132.05	213,331
9/14/2022	Buy	57,100	$104.43	$5,962,953.00	108,178
8/19/2022	Buy	46,170	$108.28	$4,999,287.60	51,078

Michael Andrew Chambers Buying and Selling Activity at Sarepta Therapeutics

Sarepta Therapeutics Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $115.62

$114.37

$117.74

50 Day Range

MA: $126.52

$115.62

$141.53

2 Week Range

Now: $115.62

$55.25

$159.89

Volume

641,236 shs

Average Volume

568,956 shs

Market Capitalization

$10.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story